[1]俞心怡,吴 培,胡楠清,等.短缺药品储备政策的实施现状与优化——以江苏省为例[J].卫生经济研究,2021,38(11):29-32.
 YU Xin-yi,WU Pei,HU Nan-qing,et al.Implementation Status and Optimization of Shortage Drug Reserve Policy——A Case Study of Jiangsu Province[J].Journal Press of Health Economics Research,2021,38(11):29-32.
点击复制

短缺药品储备政策的实施现状与优化
——以江苏省为例
分享到:

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年11期
页码:
29-32
栏目:
药械管理
出版日期:
2021-10-29

文章信息/Info

Title:
Implementation Status and Optimization of Shortage Drug Reserve Policy
——A Case Study of Jiangsu Province
作者:
俞心怡1吴 培1胡楠清1李 军1茅宁莹1
1.中国药科大学国际医药商学院,江苏 南京 211198
Author(s):
YU Xin-yi WU Pei HU Nan-qing LI Jun MAO Ning-ying
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
短缺药品药品储备承储企业
Keywords:
shortage drug drug reserve storage enterprise
分类号:
R95
文献标志码:
A
摘要:
深入分析我国短缺药品储备政策的发展历程及现状,探究现阶段存在的不足,结合江苏省经验,提出进一步优化政策的建议:细化各部门职责,加强短缺药品信息沟通;适当延长承储企业更换调整的周期;科学优化储备品种结构,适度加大储备资金投入;政府-企业-公众协同,应对药品短缺问题。
Abstract:
This paper makes an in-depth analysis of the development process and status of shortage drug reserve policy in China, analysis the shortcomings at the present stage, and put forward some suggestions for further optimizing the policy based on the experience of Jiangsu Province: refining the responsibilities of various departments and strengthening the communication of shortage drug information; appropriately prolonging the period of replacement and adjustment of storage enterprises; scientifically optimizing the variety structure of reserves and appropriately increasing the investment of reserve funds; by government-enterprise-public coordination to deal with the problem of drug shortage.

参考文献/References:

[1] 国务院关于印发“十三五”深化医药卫生体制改革规划的通知[J].中华人民共和国国务院公报,2017(3):66-81.
[2] 肖珊,邓艾平,刘珏,等.新型冠状病毒肺炎疫情期间药品供应保障实践与相关问题探讨[J].中国医院药学杂志,2020,40(12):1300-1302,1353.
[3] 李敏,汤少梁.基于供给侧改革的廉价药可及性提升路径研究[J].中国卫生事业管理,2016,33(11):831-834.
[4] 崔湲.完善我国国家医药储备制度研究[J].经济研究参考,2014(61):36-41.
[5] 臧彦卿.关于完善地方医药储备体制的思考[J].机构与行政,2020(4)::22-25.
[6] 臧彦卿.优化地方医药储备体制的实践进路[J].中共青岛市委党校.青岛行政学院学报,2020(3):54-57.
[7] 薛原,程守勤.江苏“组合拳”保障短缺药[J].中国卫生,2017(9):76.
[8] FDA.Drug Shortages:Root Causes and Potential Solutions[EB/OL].(2020-02-21)[2021-03-23].https:// www.fda.gov/drugs/drug-shortages/report-drug-shortages-rootcauses-and-potential-solutions.
[9] 黄润青,李璠.基于层次分析法的短缺药品清单遴选指标体系的构建研究[J].中国卫生政策研究,2020,13(6):8-13.

相似文献/References:

[1]邵 蓉,孙海顺,张 梦.英国短缺药品联络人报告制度对我国的启示[J].卫生经济研究,2016,(12):22.
[2]李 勇,赵梦蕊,马爱霞,等.我国仿制药一致性评价对药品短缺的影响分析[J].卫生经济研究,2017,(05):47.
[3]盛亚楠,李 勇,马爱霞,等.我国短缺药品供应保障政策研究[J].卫生经济研究,2017,(08):57.
[4]葛 靖,王淑庆,常 峰,等.上海市短缺药品特点及使用变化情况研究[J].卫生经济研究,2020,(02):59.
 GE Jing,WANG Shu-qing,CHANG Feng,et al.Study on the Characteristics and Changes of Drugs in Shortage in Shanghai[J].Journal Press of Health Economics Research,2020,(11):59.
[5]朱雅萌,傅鸿鹏.我国短缺药品现状分析与思考[J].卫生经济研究,2021,38(6):59.
 ZHU Ya-meng,FU Hong-peng.Analysis and Reflection on the Current Situation of Drug Shortage in China[J].Journal Press of Health Economics Research,2021,38(11):59.
[6]王丽娜,李亦蕾,王煜昊,等.我国短缺药品的采购方式及优化研究[J].卫生经济研究,2024,41(02):36.
 WANG Lina,LI Yilei,WANG Yuhao,et al.Study on the Procurement Model and Optimization of Drug Shortage in China[J].Journal Press of Health Economics Research,2024,41(11):36.

更新日期/Last Update: 2021-10-29